[go: up one dir, main page]

LV11987B - METHOD OF PREVENTION OR TREATMENT OF MEETING - Google Patents

METHOD OF PREVENTION OR TREATMENT OF MEETING Download PDF

Info

Publication number
LV11987B
LV11987B LVP-97-182A LV970182A LV11987B LV 11987 B LV11987 B LV 11987B LV 970182 A LV970182 A LV 970182A LV 11987 B LV11987 B LV 11987B
Authority
LV
Latvia
Prior art keywords
igf
hgh
rats
fat
use according
Prior art date
Application number
LVP-97-182A
Other languages
English (en)
Latvian (lv)
Other versions
LV11987A (lv
Inventor
Ross G. Clark
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of LV11987A publication Critical patent/LV11987A/xx
Publication of LV11987B publication Critical patent/LV11987B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-97-182A 1992-10-29 1997-09-25 METHOD OF PREVENTION OR TREATMENT OF MEETING LV11987B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96862392A 1992-10-29 1992-10-29

Publications (2)

Publication Number Publication Date
LV11987A LV11987A (lv) 1998-03-20
LV11987B true LV11987B (en) 1998-06-20

Family

ID=25514516

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-97-182A LV11987B (en) 1992-10-29 1997-09-25 METHOD OF PREVENTION OR TREATMENT OF MEETING

Country Status (13)

Country Link
EP (1) EP0669832B1 (fr)
JP (1) JPH08502969A (fr)
AT (1) ATE143267T1 (fr)
AU (1) AU675996B2 (fr)
CA (1) CA2145501C (fr)
DE (1) DE69305091T2 (fr)
DK (1) DK0669832T3 (fr)
ES (1) ES2095086T3 (fr)
GR (1) GR3022074T3 (fr)
LV (1) LV11987B (fr)
MD (1) MD1486G2 (fr)
TJ (1) TJ286B (fr)
WO (1) WO1994009813A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JPH08305892A (ja) * 1995-05-11 1996-11-22 Sega Enterp Ltd 画像処理装置及びこれを備えたゲーム装置
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP1117425A2 (fr) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Procedes pour traiter les troubles non thyroidiens
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
EP1670413A4 (fr) 2003-08-21 2009-07-08 Tercica Inc Methodes destinees a reduire la graisse viscerale par augmentation des taux du facteur de croissance insulinomimetique de type i (igf-i)
RU2317118C1 (ru) * 2006-09-21 2008-02-20 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения липодистрофии у больных сахарным диабетом
US20250270167A1 (en) * 2021-07-29 2025-08-28 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid and use thereof, recombinant protein containing same and recombinant protein conjugate
US20240317832A1 (en) * 2021-07-29 2024-09-26 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent

Also Published As

Publication number Publication date
EP0669832A1 (fr) 1995-09-06
DE69305091T2 (de) 1997-03-13
ES2095086T3 (es) 1997-02-01
DK0669832T3 (da) 1997-03-17
AU5451294A (en) 1994-05-24
TJ286B (en) 2000-12-13
MD1486F2 (en) 2000-06-30
GR3022074T3 (en) 1997-03-31
JPH08502969A (ja) 1996-04-02
WO1994009813A1 (fr) 1994-05-11
ATE143267T1 (de) 1996-10-15
AU675996B2 (en) 1997-02-27
MD960245A (en) 1997-12-31
MD1486G2 (ro) 2001-11-30
EP0669832B1 (fr) 1996-09-25
CA2145501C (fr) 2004-08-10
LV11987A (lv) 1998-03-20
DE69305091D1 (de) 1996-10-31
CA2145501A1 (fr) 1994-05-11

Similar Documents

Publication Publication Date Title
US5597797A (en) Method for treatment or prevention of obesity
US5374620A (en) Growth-promoting composition and its use
US5935924A (en) Treatment of congestive heart failure
US5681814A (en) Formulated IGF-I Composition
US5610134A (en) Treatment of congestive heart failure
EP0602050B1 (fr) Procede de stimulation de la reponse immunitaire
WO1993000109A1 (fr) Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance
US5661122A (en) Treatment of congestive heart failure
HK1007954B (en) The combination of growth hormone and insulin-like growth factor-i enhances growth
AU675996B2 (en) Method for treatment or prevention of obesity
IE922113A1 (en) Method of stimulating immune response
WO2011050008A2 (fr) Polythérapie comprenant l'administration d'un amylinomimétique et d'un peptidomimétique de pyy pour obtenir une perte de poids et pour traiter l'obésité et les états pathologiques et les troubles métaboliques associés
US20070161551A1 (en) Methods and compositions for the treatment of lipodystrophy
US20070037861A1 (en) Enhanced method of treatment of growth disorders
AU2005210093A1 (en) Methods and compositions for the treatment of lipodystrophy
MXPA96004803A (en) Combination of hormone of growth and factor similar decrease to insulin for the treatment of the cardiac failure congest
HK1003418B (en) The combination of growth hormone and insulin-like growth factor, for treating congestive heart failure